- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04007393
SMART Use of Medication for the Treatment of Adolescent Severe Obesity (SMART)
November 20, 2023 updated by: University of Minnesota
This study will examine the timing and sequence of using adjunct obesity pharmacotherapy for adolescents with severe obesity who do not respond to lifestyle modification therapy alone.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This project is studying the best time to add weight loss medication to diet and exercise for helping adolescents who carry extra weight.
All participants start with a lifestyle modification program and some participants may also receive study medication.Participants must be 12-17 years of age and carry extra weight.
The program will last for 48 weeks.
Study Type
Interventional
Enrollment (Estimated)
150
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Claudia Fox, MD, MPH
- Phone Number: (612)626-6616
- Email: lusc0001@umn.edu
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55414
- University of Minnesota
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years to 17 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Provision of signed and dated informed assent form;
- Provision of signed and dated informed parental consent form from at least 1 legal parent/guardian;
- Stated willingness to comply with all study procedures and availability for the duration of the study;
- BMI >/= 1.2 times the 95th percentile or BMI >/= 35 Kg/m2, whichever is lower;
- Tanner stage >/= 2;
- Male or female, aged 12-17 at time of consenting;
- For females of reproductive potential: when sexually active, agreement to use highly effective contraception (oral contraceptive pill, intra-uterine device (IUD), or implant) during study participation;
- For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner.
Exclusion Criteria:
- Contraindications to phentermine or topiramate use according to package inserts, including: history of glaucoma; current or recent (< 14 days) use of monoamine oxidase inhibitor; known hypersensitivity to sympathomimetic amines; current pregnancy, plans to become pregnant, or if sexually active refusal to use 2 forms of birth control; history of cardiac disease including coronary artery disease; clinically significant cardiac arrhythmias; heart failure or uncontrolled hypertension;
- Diabetes (type 1 or 2);
- Presence of cardiac pacemaker;
- Current or recent (<6 months prior to enrollment) use of weight loss medication(s);
- Current use of weight-altering medication(s) (e.g., atypical antipsychotic, metformin) unless dose has been stable for past 6 months;
- Current use of other sympathomimetic amine such as attention-deficit hyperactivity disorder (ADHD) stimulants;
- Seizure disorder (other than infantile febrile seizure);
- Previous bariatric surgery;
- Recent initiation of change in dose (< 3 months prior to enrollment) of anti-hypertensive or lipid medication(s);
- Tobacco use
- History of or current diagnosis of schizophrenia, psychosis, mania, chemical dependency;
- Unstable depression or anxiety that has required hospitalization in the past year;
- Any history of suicide attempt;
- Suicidal ideation or self-harm within 12 months prior to enrollment;
- Bicarbonate < 18 mmol/L;
- Creatinine > 1.2 mg/dL;
- History of cholelithiasis;
- History of nephrolithiasis;
- Untreated thyroid disorder;
- Hyperthyroidism;
- Breastfeeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: LSMT x 12 weeks
Participants in this arm will start LSMT at baseline and have a weight loss response assessment at T=12 weeks: if body mass index (BMI) is down 5% at T=12 weeks, the participant will continue with LSMT for the remainder of the study (i.e. for another 36 weeks); if BMI is not down 5% at T=12 weeks, the participant will add phentermine to LSMT (phentermine+LSMT) and undergo a second weight loss response assessment after 12 weeks of phentermine+LSMT; i.e. at T=24 weeks.
At T=24 weeks, if BMI is down 5% with phentermine+LSMT, the participant will continue with phentermine+LSMT for the the remainder of study (i.e. for another 24 weeks); if BMI is not down by 5% at T=24 weeks, the participant will be randomized to topiramate+phentermine+LSMT or topiramate+placebo+LSMT for the remainder of the study (i.e. for another 24 weeks).
|
LSMT will consist of both in-person and by telephone sessions delivered throughout the entirety of the 48-week intervention phase.
Each session will last 30-60 minutes.
A trained study coordinator (a registered dietician or someone trained by our registered dietician) will delivery this therapy which consists of counseling using education, goal setting and barrier reduction.
Topics covered will include calories, tracking, healthy food choices, reducing high fat, added sugar foods, setting goals and portions, changing the quality of your diet, volumetrics, purposeful activity, quick and easy meals, problem solving, food cues and eating patterns, emotional eating, accurate tracking, eating away from home, unhelpful thoughts, structured menus and the role of protein, social cues, managing stress, slips and relapse prevention, long-term physical activity and overcoming obstacles, high-risk situation and keys to success, motivation and looking to the future (long-term plans).
Phentermine will be started only if a participant does not lose 5% of BMI after 12 or 24 weeks of LSMT depending on their random assignment.
Subjects will take 15 mg of phentermine every morning for 12 weeks at which time there will be an assessment of weight loss.
Subjects who achieve 5% or more BMI reduction after 12 weeks of phentermine will continue 15 mg every morning for the remainder of the study (through week 48) along with their LSMT.
Participants who do no not achieve at least 5% BMI reduction after 12 weeks of phentermine+LSMT will be re-randomized 1:1 to either topiramate+phentermine+LSMT or topiramate+placebo+LSMT. Topiramate dosing will begin at 50 mg every morning for the first 7 days, and then increase to 100 mg every morning through week 48.
At the end of week 48 the taper off will be 50 mg every morning for 7 days and then discontinue.
|
Other: LSMT x 24 weeks
Participants in this arm will start LSMT at baseline and have a weight loss response assessment at T=24 weeks: if body mass index (BMI) is down 5% at T=24 weeks, the participant will continue with LSMT for the remainder of the study (i.e. for another 24 weeks); if BMI is not down 5% at T=24 weeks, the participant will add phentermine to LSMT (phentermine+LSMT) and undergo a second weight loss response assessment after 12 weeks of phentermine+LSMT; i.e. at T=36 weeks.
At T=36 weeks, if BMI is down 5% with phentermine+LSMT, the participant will continue with phentermine+LSMT for the the remainder of study (i.e. for another 12 weeks); if BMI is not down by 5% at T=36 weeks, the participant will be randomized to topiramate+phentermine+LSMT or topiramate+placebo+LSMT for the remainder of the study (i.e. for another 12 weeks).
|
LSMT will consist of both in-person and by telephone sessions delivered throughout the entirety of the 48-week intervention phase.
Each session will last 30-60 minutes.
A trained study coordinator (a registered dietician or someone trained by our registered dietician) will delivery this therapy which consists of counseling using education, goal setting and barrier reduction.
Topics covered will include calories, tracking, healthy food choices, reducing high fat, added sugar foods, setting goals and portions, changing the quality of your diet, volumetrics, purposeful activity, quick and easy meals, problem solving, food cues and eating patterns, emotional eating, accurate tracking, eating away from home, unhelpful thoughts, structured menus and the role of protein, social cues, managing stress, slips and relapse prevention, long-term physical activity and overcoming obstacles, high-risk situation and keys to success, motivation and looking to the future (long-term plans).
Phentermine will be started only if a participant does not lose 5% of BMI after 12 or 24 weeks of LSMT depending on their random assignment.
Subjects will take 15 mg of phentermine every morning for 12 weeks at which time there will be an assessment of weight loss.
Subjects who achieve 5% or more BMI reduction after 12 weeks of phentermine will continue 15 mg every morning for the remainder of the study (through week 48) along with their LSMT.
Participants who do no not achieve at least 5% BMI reduction after 12 weeks of phentermine+LSMT will be re-randomized 1:1 to either topiramate+phentermine+LSMT or topiramate+placebo+LSMT. Topiramate dosing will begin at 50 mg every morning for the first 7 days, and then increase to 100 mg every morning through week 48.
At the end of week 48 the taper off will be 50 mg every morning for 7 days and then discontinue.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent change in body mass index (BMI)
Time Frame: Baseline, 12-, 24-, 36-, and 48 weeks
|
Body mass index is a measure of body fat based on height and weight.
|
Baseline, 12-, 24-, 36-, and 48 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Claudia Fox, MD, MPH, University of Minnesota
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 21, 2019
Primary Completion (Estimated)
August 31, 2024
Study Completion (Estimated)
August 31, 2025
Study Registration Dates
First Submitted
June 28, 2019
First Submitted That Met QC Criteria
July 1, 2019
First Posted (Actual)
July 5, 2019
Study Record Updates
Last Update Posted (Estimated)
November 22, 2023
Last Update Submitted That Met QC Criteria
November 20, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Overnutrition
- Nutrition Disorders
- Overweight
- Body Weight
- Obesity
- Pediatric Obesity
- Obesity, Morbid
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Anticonvulsants
- Appetite Depressants
- Anti-Obesity Agents
- Central Nervous System Stimulants
- Sympathomimetics
- Topiramate
- Phentermine
Other Study ID Numbers
- PEDS-2019-26512
- 1R01DK119456 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adolescent Obesity
-
National University of MalaysiaUniversiti Putra Malaysia; University of RoehamptonCompletedAdolescent Obesity | Adolescent Behavior | Adolescent OverweightMalaysia
-
University of OxfordOxford Brookes UniversityRecruitingOverweight/Obesity, AdolescentUnited Kingdom
-
VIVUS LLCCompletedAdolescent Obesity | Obesity in Adolescence | Adolescent OverweightUnited States
-
Delta University for Science and TechnologyCompletedObesity, Adolescent | Adolescent DevelopmentEgypt
-
State University of New York at BuffaloNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedObesity, Adolescent | Adolescent Behavior
-
Children's Hospital of PhiladelphiaNational Institutes of Health (NIH)Not yet recruitingAdolescent Obesity | Diet, Healthy | Adolescent Overweight
-
University of BedfordshireCompletedInsulin Resistance | Adolescent Obesity | Adolescent BehaviorUnited Kingdom
-
Fundació Sant Joan de DéuNot yet recruitingObesity, Childhood | Obesity, AdolescentSpain
-
Guangzhou Sport UniversityUnknownChildhood Obesity | Adolescent ObesityChina
-
University of AarhusActive, not recruitingDiabetes | Childhood Obesity | Adolescent Obesity | Overweight and Obesity | Adolescent OverweightDenmark
Clinical Trials on Lifestyle Modification Therapy (LSMT)
-
Massachusetts General HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
University of OuluOulu University Hospital; Oulu Deaconess Institute Foundation srCompletedObesity | Physical Activity | Weight Loss | Healthy Obesity, MetabolicallyFinland
-
University of PennsylvaniaSt. Luke's-Roosevelt Hospital CenterCompletedObesity | OverweightUnited States
-
Clínica BazterricaWithdrawn
-
Universität Duisburg-EssenCharite University, Berlin, Germany; University of Witten/Herdecke; Kliniken... and other collaboratorsCompletedHypertension | Metabolic SyndromeGermany
-
National Institute of Diabetes and Digestive and...University of Massachusetts, WorcesterCompleted
-
Universiti Putra MalaysiaRecruitingEducational Materials (ST-NEPCO) During Nutrition Counselling for Obese ChildrenMalaysia
-
VA Office of Research and DevelopmentActive, not recruitingDiabetes | Impaired Glucose Tolerance | NeuropathyUnited States
-
King Abdullah International Medical Research CenterCompleted
-
Medical University of South CarolinaCompletedWeight Loss | Heart Failure, DiastolicUnited States